Swiss Re Tackles Longevity Drug Impact With Life Policy Advice

Swiss Re AG issued guidance for underwriters on how to assess life insurance applications of people who show signs of using medications for longevity purposes.

Metformin, traditionally used to manage type 2 diabetes, and rapamycin, an immunosuppressant developed for organ transplant recipients, are part of a growing list of substances being explored for anti-aging purposes, Swiss Re said. In some cases, the medications are being self-prescribed, the reinsurer said.